MRK241011C109000
- 0.80
- -0.80-50.00%
Merck & Co Newsroom
Is Merck & Co Inc. (MRK) the Best Quality Stock to Buy According to Analysts?
Goldman Sees a 'Relief Rally' Potential for These Option Calls Ahead of Earnings
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Truist lowers Merck's target price to $132.
Truist Securities: Lowered merck's target price from $143 to $132.
Merck & Co Analyst Ratings
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $136
Trump Vs Harris: Democratic Candidate Holds Narrow Lead Over Ex-president In Tightening Race, New Poll Shows
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
New Data to Be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Express News | New Data to Be Presented at Idweek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $132
Express News | Merck & Co Inc : Truist Securities Cuts Target Price to $132 From $143
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer
Merck & Co., Inc. (MRK) Got Off to a Strong Start in January, Says Ray Dalio
Express News | Obesity Drug Coverage Could Boost Spending By $35B Through 2034
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination With KEYTRUDA (Pembrolizumab)
Mestag Therapeutics Enters Into A License And Collaboration Agreement With MSD To Identify Novel Targets For The Development Of Therapies Against Inflammatory Diseases; Exclusively Deploys Mestag's Proprietary RAFT Platform To Interrogate The...
Merck Posts Late-stage Trial Win for Keytruda in Head and Neck Cancer
Express News | Merck & Co Inc - Os Results Did Not Reach Statistical Significance in CPS ≥10 Patients